Xin Lang Cai Jing·2025-05-01 01:24Group 1 - Fosun Pharma (600196.SH) reported its Q1 2025 financial results on April 30, 2025, with 45 institutional investors disclosing holdings in the company, totaling 1.12 billion shares, which represents 41.92% of the total share capital [1] - The top ten institutional investors include Shanghai Fosun High Technology (Group) Co., Ltd., Hong Kong Central Clearing Limited, and several major banks and funds, with their combined holdings accounting for 41.34% of the total shares, a decrease of 0.18 percentage points from the previous quarter [1] Group 2 - In the public fund sector, 17 funds increased their holdings compared to the previous period, with notable funds including Tianhong Guozhen Biomedicine ETF and GF Innovation Drug ETF, representing an increase of 0.10% [2] - Conversely, 21 public funds reduced their holdings, including Huatai-PB CSI 300 ETF and E Fund CSI 300 Medicine ETF, with a decrease of 0.14% [2] - One new public fund was disclosed during this period, namely Dongfanghong CSI 500 Index Enhanced Initiation A, while 348 funds were not disclosed compared to the previous quarter [2]